The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 1167-1183

  Berezhkovskiy, Leonid M ^a  

^a GENENTECH INC   (United States)

Author keywords

Dispersion model; Drug ionization; Extra and intracellular water distribution; Hepatic clearance; Hepatic uptake and efflux; Metabolic elimination; Parallel tube model; PBPK equation; Pharmacokinetics; Physiological model; Well stirred model

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DILTIAZEM; DIPHENHYDRAMINE; IMIPRAMINE; KETAMINE; LIDOCAINE; LORCAINIDE; METOPROLOL; NALOXONE; PROPAFENONE; PROPRANOLOL; QUINIDINE; TENOXICAM; TIMOLOL; TOLBUTAMIDE; VERAPAMIL;

ARTICLE; CALCULATION; CELL PH; DISPERSION; DRUG ELIMINATION; DRUG UPTAKE; IONIZATION; LIVER CELL; LIVER CLEARANCE; PARTITION COEFFICIENT; PLASMA; PROTEIN BINDING; TISSUE WATER;

EID: 79251546082     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22324     Document Type: Article

References (67)

1. Roberts MS, Rowland M. 1986. A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. Pharmacokinet Biopharm 14:261-288.
2. Gillette JR. 1971. Factors affecting drug metabolism. Ann NY Acad Sci 179:43-66.
3. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
4. Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE. 2009. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. J Pharm Sci 98:1922-1927.
5. Berezhkovskiy LM. 2010. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood- tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm. Sci 99: 475-485.
6. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
7. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 Suppl 1:S41-S67.
8. Turner D. 2008. Simcyp population-based ADME simulator user manual, version 8. pp 232 pages including appendices and references.Simcyp Limited, Blades Enterprise Centre, Sheffield, UK.
9. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
10. Lesser GT, Deutsch S. 1967. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 23:621-630.
11. Crandall DL, Hausman GJ, Kral JG. 1997. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 4:211-232.
12. Baker M, Parton T. 2007. Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica 37:1110-1134.
13. Csajka C, Verotta D. 2006. Pharmacokinetic-pharmacodynamic modelling: History and perspectives. J Pharmacokinet Pharmacodyn 33:227-279.
14. Berezhkovskiy LM. 2010. On the influence of protein binding on pharmacological activity of drugs. J Pharm Sci 99:2153-2165.
15. Berezhkovskiy LM. 2009. Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters. J Pharm Sci 98:748-762.
16. Peinhardt G, Wiese M. 2001. Microionization constants: Novel approach for the determination of the zwitterionic equilibrium of hydroxyphenylalkylamines by photometric titration. Int J Pharm 215:83-89.
17. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
18. Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab Dispos 30:892-896.
19. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
20. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. 1996. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
21. Schulz P, Turner-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF. 1983. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 33:360-366.
22. Eberts FS, Philopoulos Y, Reineke LM, Vliek RW. 1980. Disposition of 14C-alprazolam, a new anxiolytic-antidepressant, in man. Pharmacologist 22:279.
23. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. 1984. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84:452-456.
24. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. 1993. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276.
25. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 73:147-171.
26. Gammans RE, Mayol RF, LaBudde JA. 1986. Metabolism and disposition of buspirone. Am J Med 80:41-51.
27. Maxwell JD, Carrella M, Parkes JD, Williams R, Mould GP, Curry SH. 1972. Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci 43:143-151.
28. Dahl SG, Strandjord RE. 1974. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther. 21:437-448.
29. Lund A. 1980. The distribution of chlorpromazine between plasma and erythrocytes. Acta Pharmacol Toxicol 47:300-304.
30. Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J. 1988. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34:445-449.
31. Brøsen K, Gram LF. 1988. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43:400-406.
32. Smith MS, Verghese CP, Shand DG, Pritchett EL. 1983. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol 51:1369-374.
33. Echizen H, Eichelbaum M. 1986. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 11:425-449.
34. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. 1986. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 26:529-533.
35. Abernethy DR, Greenblatt DJ, Shader RI. 1985. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 232:183-188.
36. Sallee FR, Pollock BG. 1990. Comparison of the effects of desipramine on noradrenaline- and methoxamine-evoked venoconstriction in man. Clin Pharmacokinet 18:346-364.
37. Nagy A, Johansson R. 1975. Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn Schmiedebergs Arch Pharmacol 290:145-160.
38. Ciraulo DA, Barnhill JG, Jaffe JH. 1988. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509-518.
39. White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. 1985. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:197-203.
40. Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. 1984. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther 35:695-701.
41. Remmel RP, Copa AK, Angaran DM. 1991. The effects of hemodilution, pH, and protamine on lidocaine plasma protein binding and red blood-cell uptake in vitro. Pharm Res 8:127-130.
42. Klotz U, Müller-Seydlitz P, Heimburg P. 1978. Pharmacokinetics of lorcainide in man: A new antiarrhythmic agent. Clin Pharmacokinet 3:407-418.
43. Somani P, Fraker TD Jr, Temesy-Armos PN. 1987. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardixac function. J Clin Pharmacol 27:122-132.
44. Johansson KA, Appelgren C, Borg KO, Elofsson R. 1974. Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. Acta Pharm Suec 11:333-346.
45. Regårdh CG, Borg KO, Johansson R, Johnsson G, Palmer L. 1974. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2:347-364.
46. Regårdh CG, Jordö L, Ervik M, Lundborg P, Olsson R, Rönn O. 1981. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 6:375-388.
47. Asali LA, Brown KF. 1984. Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol 27:459-463.
48. Holford N. 1998. Clinical pharmacokinetics: Drug data handbook, 3rd ed., ADIS Press Limited Auckland, New Zealand.
49. Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB, Davies RO. 1982. Timolol and propranolol: Bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther 32:676-685.
50. Walle T, Walle UK, Cowart TD, Conradi EC. 1989. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46:257-263.
51. Bryson HM, Palmer KJ, Langtry HD, Fitton A. 1993. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 45:85-130.
52. Hughes IE, Ilett KF, Jellett LB. 1975. The distribution of quinidine in human blood. Br J Clinb Pharmacol 2:521-525.
53. Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, Smith TW, Koch-Weser J. 1977. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 2:365-378.
54. Rakhit A, Holford NH, Guentert TW, Maloney K, Riegelman S. 1984. Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm 12:1-21.
55. Guentert TW, Holford NH, Coates PE, Upton RA, Riegelman S. 1979. Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm 7:315-330.
56. Hardy BG, Schentag JJ. 1988. Lack of effect of cimetidine on the metabolism of quinidine: Effect on renal clearance. Int J Clin Pharmacol Ther Toxicol 26:388-391.
57. Lau YY, Sapidou E, Cui X, White RE, Cheng KC. 2002. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
58. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. 1977. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21:301-309.
59. Miller AK, Adir J, Vestal RE. 1990. Excretion of tolbutamide metabolites in young and old subjects. Eur J Clin Pharmacol 38:523-524.
60. Eichelbaum M, Mikus G, Vogelgesang B. 1984. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453-458.
61. McAllister RG Jr, Kirsten EB. 1982. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31:418-426.
62. Gross AS, Heuer B, Eichelbaum M. 1988. Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol 37:4623-4627.
63. Pollock AS. 1984. Intracellular pH of hepatocytes in primary monolayer culture. Am J Physiol 246(5 Pt 2):F738-744.
64. Kim JH, Johannes L, Goud A, Antony C, Lingwood CA, Daneman R, Grinstein S. 1998. Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. Proc Natl Acad Sci USA 95: 2997-3002.
65. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tuAe" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-53.
66. Veng-Pedersen P. 2001. Noncompartmentally-based pharmacokinetic modeling. Adv Drug Deliv Rev 48:265-300.
67. Berezhkovskiy LM. 2007. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 96:3432-3443.